Apogee Therapeutics (APGE) Cash & Current Investments (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Cash & Current Investments data on file, last reported at $1.1 billion in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $1.1 billion, up 106.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 106.48% YoY), and the FY2025 annual result was $730.2 million, up 40.25% from the prior year.
• Cash & Current Investments climbed to $1.1 billion in Q1 2026 per APGE's latest filing, from $730.2 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $1.1 billion in Q1 2026 and troughed at $5.0 million in Q2 2022.
• A 5-year average of $498.2 million and a median of $517.0 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments surged 2415.08% in 2023, then plunged 37.11% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $151.9 million in 2022, then jumped by 160.36% to $395.5 million in 2023, then surged by 31.66% to $520.7 million in 2024, then soared by 40.25% to $730.2 million in 2025, then soared by 45.15% to $1.1 billion in 2026.
• Business Quant data shows APGE's Cash & Current Investments at $1.1 billion in Q1 2026, $730.2 million in Q4 2025, and $527.3 million in Q3 2025.